Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial
Executive Summary
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.